Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT Jr SC: Efgartigimod PH20 SC in Pediatric Generalized Myasthenia Gravis
NCT06392386Phase 3Recruiting
- Sponsor
- argenx
- Start
- Jun 2024
- Primary completion
- Sep 2027
- Modality
- Antibody Fragments
- Countries
- 14
01
Overview
A Phase 3 trial of efgartigimod alfa + hyaluronidase-qvfc in myasthenia gravis (MG), sponsored by argenx. Started Jun 2024; status: recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06392386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06392386.